IL161921A0 - 3-Cyanoquinolines as inhibitors of egf-r and her2 kinases - Google Patents

3-Cyanoquinolines as inhibitors of egf-r and her2 kinases

Info

Publication number
IL161921A0
IL161921A0 IL16192102A IL16192102A IL161921A0 IL 161921 A0 IL161921 A0 IL 161921A0 IL 16192102 A IL16192102 A IL 16192102A IL 16192102 A IL16192102 A IL 16192102A IL 161921 A0 IL161921 A0 IL 161921A0
Authority
IL
Israel
Prior art keywords
cyanoquinolines
egf
inhibitors
her2 kinases
her2
Prior art date
Application number
IL16192102A
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of IL161921A0 publication Critical patent/IL161921A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
IL16192102A 2001-11-27 2002-11-26 3-Cyanoquinolines as inhibitors of egf-r and her2 kinases IL161921A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33356801P 2001-11-27 2001-11-27
PCT/US2002/037918 WO2003050090A1 (en) 2001-11-27 2002-11-26 3-cyanoquinolines as inhibitors of egf-r and her2 kinases

Publications (1)

Publication Number Publication Date
IL161921A0 true IL161921A0 (en) 2005-11-20

Family

ID=23303345

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16192102A IL161921A0 (en) 2001-11-27 2002-11-26 3-Cyanoquinolines as inhibitors of egf-r and her2 kinases

Country Status (24)

Country Link
US (1) US6821988B2 (en)
EP (1) EP1448531B1 (en)
JP (1) JP2005514384A (en)
KR (1) KR20050044599A (en)
CN (1) CN1659145A (en)
AR (1) AR037438A1 (en)
AT (1) ATE370123T1 (en)
AU (1) AU2002359489B2 (en)
BR (1) BR0214485A (en)
CA (1) CA2467573A1 (en)
CO (1) CO5580828A2 (en)
DE (1) DE60221886D1 (en)
EC (1) ECSP045122A (en)
HU (1) HUP0402228A2 (en)
IL (1) IL161921A0 (en)
MX (1) MXPA04004969A (en)
NO (1) NO20042634L (en)
NZ (1) NZ533118A (en)
PL (1) PL370137A1 (en)
RU (1) RU2309150C2 (en)
TW (1) TW200300348A (en)
UA (1) UA77469C2 (en)
WO (1) WO2003050090A1 (en)
ZA (1) ZA200405025B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3712393B2 (en) 2000-10-20 2005-11-02 エーザイ株式会社 Nitrogen-containing aromatic ring derivatives
AU2003249212C1 (en) * 2002-07-15 2011-10-27 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
CA2533126A1 (en) * 2003-08-01 2005-03-03 Wyeth Holdings Corporation Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
AU2003304497B2 (en) * 2003-09-15 2010-06-24 Wyeth Llc Substituted quinolines as protein tyrosine kinase enzyme inhibitors
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
US7365203B2 (en) * 2003-09-15 2008-04-29 Wyeth Process for the synthesis of 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-ethoxy-quinoline-3-carbonitrile
EP2213661B1 (en) * 2003-09-26 2011-07-20 Exelixis Inc. c-Met Modulators and Methods of Use
US7781591B2 (en) 2006-06-13 2010-08-24 Wyeth Llc Substituted 3-cyanopyridines as protein kinase inhibitors
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
SG155222A1 (en) 2004-08-13 2009-09-30 Genentech Inc Thiazole based inhibitors of atp-utilizing enzymes
ATE428421T1 (en) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd MEDICAL COMPOSITION WITH IMPROVED STABILITY AND REDUCED GELING PROPERTIES
TW200616612A (en) * 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention
CN113952338A (en) 2005-02-03 2022-01-21 综合医院公司 Methods of treating gefitinib resistant cancers
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
US7624279B2 (en) * 2005-06-29 2009-11-24 Lenovo Singapore Pte. Ltd. System and method for secure O.S. boot from password-protected HDD
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
BRPI0618042A2 (en) 2005-11-04 2011-08-16 Wyeth Corp uses of a rapamycin and herceptin, product, pharmaceutical package, and, pharmaceutical composition
US20090209580A1 (en) 2006-05-18 2009-08-20 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
CA2654515C (en) * 2006-06-13 2014-04-01 Wyeth Substituted 3-cyanopyridines as protein kinase inhibitors
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
CN101600694A (en) 2007-01-29 2009-12-09 卫材R&D管理有限公司 Composition for treatment of undifferentiated-type of gastric cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101513326B1 (en) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 Combination of anti-angiogenic substance and anti-tumor platinum complex
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
SI2310011T1 (en) 2008-06-17 2013-10-30 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
BRPI0916694B1 (en) 2008-08-04 2021-06-08 Wyeth Llc use of neratinib in combination with capecitabine to treat erbb-2 positive metastatic breast cancer, kit and product comprising the same
ITMI20082336A1 (en) * 2008-12-29 2010-06-30 Univ Parma COMPOUNDS IRREVERSIBLE EGFR INHIBITORS WITH ANTI-PROLIFERATIVE ACTIVITY
TWI641593B (en) 2009-01-16 2018-11-21 美商艾克塞里克斯公司 Pharmaceutical composition comprising malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide and use thereof
EP4218760A3 (en) 2009-04-06 2023-08-16 Wyeth LLC Treatment regimen utilizing neratinib for breast cancer
UA108618C2 (en) 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
EP2498751B1 (en) 2009-11-09 2019-04-03 Wyeth LLC Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
EP3222620B1 (en) * 2010-06-09 2019-11-20 Tianjin Hemay Oncology Pharmaceutical Co., Ltd. Cyanoquinoline derivatives
EP2586443B1 (en) 2010-06-25 2016-03-16 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
CN103313713B (en) * 2010-08-26 2014-12-31 和谐进化股份有限公司 Receptor-type kinase modulator and method for treating polycystic kidney disease
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CN102675287A (en) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 Pharmaceutically acceptable salts of (E)-N-(4-((3-chloro-4-(2-pyridyl methoxy) phenyl) amino)-3-cyano-7-ethyoxyl-6-quinolyl)-3-((2R)-1-methyl pyrrolidine-2-propyl)-2-acrylamide, preparation method and application of salts in medicines
KR101762999B1 (en) 2011-04-18 2017-07-28 에자이 알앤드디 매니지먼트 가부시키가이샤 Therapeutic agent for tumor
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
WO2014098176A1 (en) 2012-12-21 2014-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Amorphous form of quinoline derivative, and method for producing same
CN103214489B (en) * 2013-02-25 2016-10-26 中国人民解放军第二军医大学 One class Mutiple Targets inhibitors of kinases with anti-tumor activity and preparation method thereof
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103304494B (en) * 2013-06-20 2015-05-27 河北大学 Indene (1,2-b) quinoxaline-11-ketoxime derivatives and preparation method as well as application thereof
CA2957005C (en) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
PL3263106T3 (en) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR20170122809A (en) 2015-03-04 2017-11-06 머크 샤프 앤드 돔 코포레이션 A combination of a PD-1 antagonist and a VEGFR / FGFR / RET tyrosine kinase inhibitor to treat cancer
WO2016204193A1 (en) 2015-06-16 2016-12-22 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ Anticancer agent
US10774068B2 (en) * 2015-06-25 2020-09-15 The Scripps Research Institute Composition and methods for inhibiting mammalian sterile 20-like kinase 1
US20190016703A1 (en) * 2015-12-30 2019-01-17 Dana-Farber Cancer Institute, Inc. Bifunctional compounds for her3 degradation and methods of use
US10828305B2 (en) 2016-03-01 2020-11-10 Shanghai Pharmaceuticals Holding Co., Ltd. Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use
KR20190013553A (en) 2017-07-28 2019-02-11 주식회사유한양행 Improved process for preparing aminopyrimidine derivatives
CN110452232A (en) * 2019-09-17 2019-11-15 北京振东光明药物研究院有限公司 Afatinib impurity compound and the preparation method and application thereof
CN111995618B (en) * 2020-09-02 2021-06-11 重庆医科大学 Preparation method of neratinib impurity G
CN111943933B (en) * 2020-09-02 2021-05-28 重庆医科大学 Preparation method of neratinib impurity D

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199801530T2 (en) * 1996-02-13 1998-11-23 Zeneca Limited Quinazoline derivatives as VEGF inhibitors.
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (en) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Substituted 3-cyan chinolines
US6235740B1 (en) * 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
IL142121A0 (en) * 1998-09-29 2002-03-10 American Cyanamid Co Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
JP4537582B2 (en) * 1998-09-29 2010-09-01 アメリカン・サイアナミド・カンパニー Substituted 3-cyanoquinolines as protein tyrosine kinase inhibitors
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
AU2464601A (en) * 1999-12-29 2001-07-09 Wyeth Tricyclic protein kinase inhibitors
AU2002210714A1 (en) * 2000-11-02 2002-06-11 Astrazeneca Ab Substituted quinolines as antitumor agents

Also Published As

Publication number Publication date
CN1659145A (en) 2005-08-24
RU2309150C2 (en) 2007-10-27
KR20050044599A (en) 2005-05-12
BR0214485A (en) 2004-09-14
HUP0402228A2 (en) 2005-02-28
EP1448531B1 (en) 2007-08-15
AR037438A1 (en) 2004-11-10
DE60221886D1 (en) 2007-09-27
RU2004119414A (en) 2006-02-27
US20030149056A1 (en) 2003-08-07
EP1448531A1 (en) 2004-08-25
UA77469C2 (en) 2006-12-15
CA2467573A1 (en) 2003-06-19
ECSP045122A (en) 2004-07-23
AU2002359489B2 (en) 2008-10-30
PL370137A1 (en) 2005-05-16
AU2002359489A1 (en) 2003-06-23
TW200300348A (en) 2003-06-01
US6821988B2 (en) 2004-11-23
ZA200405025B (en) 2006-12-27
NO20042634L (en) 2004-06-23
MXPA04004969A (en) 2004-08-11
NZ533118A (en) 2006-07-28
WO2003050090A1 (en) 2003-06-19
JP2005514384A (en) 2005-05-19
CO5580828A2 (en) 2005-11-30
ATE370123T1 (en) 2007-09-15

Similar Documents

Publication Publication Date Title
IL161921A0 (en) 3-Cyanoquinolines as inhibitors of egf-r and her2 kinases
HK1160859A1 (en) Inhibitors of tyrosine kinases
IL161576A0 (en) Benzimidazoles and analogues and their use as protein kinases inhibitors
HK1053832A1 (en) Inhibitors of protein kinases
MXPA03006420A (en) Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase.
SI1562589T1 (en) Diaminotriazoles useful as inhibitors of protein kinases
HK1076598A1 (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
HK1072545A1 (en) Novel inhibitors of kinases
HK1061854A1 (en) Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
AU2003256297A1 (en) Benzimidazoles and benzothiazoles as inhibitors of map kinase
AU2002308748A1 (en) Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
AU2003282891A8 (en) Novel tyrosine kinases inhibitors
EP1372654A4 (en) Quinoline inhibitors of hyak1 and hyak3 kinases
PL369742A1 (en) Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
MXPA03009257A (en) Isoxaxole derivatives as inhibitors of src and other protein kinases.
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
MXPA03006423A (en) Naphthostyril derivatives and their use as inhibitors of cyclin- dependent kinases.
AU2002306845A1 (en) Telomerase inhibitors and methods of their use
ZA200305379B (en) Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase.
AU2002303336A1 (en) Isoxaxole derivatives as inhibitors of src and other protein kinases
AU2002317319A1 (en) Quinoline derivatives and their use as tyrosine kinase inhibitors
ZA200500492B (en) Novel inhibitors of kinases
AU2002345712A1 (en) Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases